Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Anderson KC, Alsina M, Bensinger W, et al. National Comprehensive Cancer Network(NCCN). Multiple myeloma. Clinical practice guidelines in oncology. J NatI Compr Canc Netw 2007;5:118–47.
Gratwohl A, Baldomero H, Frauendorfer K, Urbano-lspizua A. EBMT activity survey2004 and changes in disease indication over the past 15 Years. Bone Marrow Transplant 2006;37: 1069–85.
Gertz MA, Lacy MQ, Dispenzieri A, et al. Impact of age and serum creatinine value onoutcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 2007;39:605–11.
Lenhoff S, Hjorth M, Holmberg E, et al. Impact of survival of high-dose therapy with autologous stem cell support in patients younger than 60 Years with newly diagnosed multiple myeloma: A population-based study. Blood 2000;95:7–11.
Morris TCM, Velangi M, Jackson G, Marks DI, Ranaghan L. Less than half of patientsaged 65 Years or under with myeloma proceed to transplantation: Results of a two region population-based survey. Br J Haematol 2005;128:510–12.
Greipp PR, San Miguel J, Dune BG, et al., International staging system for multiple myeloma. J Clin Oncol 2005;23:3412–20.
Chng WJ, Santana-Davila R, Van Wier SA, et al. Prognostic factors for hyper-diploidmyeloma: Effects of chromosome 13 deletions and IgH translocations. Leukemia 2006;20:807–13.
Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007;21:151–57.
Jaksic W, Trudel S, Chang H, et al. Clinical outcomes in t(4;14) multiple myeloma: A chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 2005;23:7069–73.
Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: The experience of the lntergroupe Francophone du Myelome. Blood 2007; 109:3489–95.
Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969;208:1680–85.
GROUP MTC. Combination chemotherapy versus MP as treatment of multiple myeloma: An overview of 6,633 patients from 27 randomised trials. J Clin Oncol 1998; 16:3832–42.
Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992;80:887–90.
Segeren CM, Sonneveld P, Van Der Holt B, et al. Vincristine, doxorubicin and dexam-ethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol 1999;105:127–30.
Hernandez JM, Garcia-Sanz R, Golvano E, et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol 2004 ; 127:159–164.
Facon T, Mary JY, Pegourie B, et al. Dexamethasone-based regimens versus mel-phalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006;107:1292–98.
Rajkumar SV, Dispenzieri A, Fonseca R, et al. Thalidomide for previously untrea-tedindolent or smoldering multiple myeloma. Leukemia 2001;15:1274–76.
Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;21:16–19.
Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Eastern Cooperative Oncology Group. Phase Ill clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431–36.
Ludwig H, Drach J, Tothová E, et al. Thalidomide-dexamethasone versus melpha-lan-prednisolone as first line treatment in elderly patients with multiple myeloma: An interim analysis. Blood 2005;106:782a.
Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 2006;367:825–31.
Facon T, Mary J, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem-cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial. Lancet 2007;370:1209–18.
Offidani M, Corvatta L, Piersantelli MN, et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 Years with newly diagnosed multiple myeloma. Blood 2006:108:2159–64.
Sidra G, Williams CD, Russet NH, Zaman S, Myers B, Byrne JL. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica 2006;91:862–63.
Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N EngI J Med 2006;354:1021–30.
Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, thalido-mide in elderly patients with multiple myeloma: up-dated results of a randomized, controlled trial. Blood 2008;doi:10.1182/Blood-2008-04-149427.
Palumbo A, Bringhen S, Falco P, et al. Time to first progression, but not ~2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. Cancer 2007; 110:824–29.
Rajkumar SV, Hayman SR, Lacy MQ, Combination therapy with lenal-idomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005 ; 106 : 4050–53.
Lacy M, Gertz M, Dispenzieri A, et al. Long term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007;82:1179–84
Rajkumar V, Jacobus S, Callander N, et al. A randomized phase III trial of lenal-idomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexam-ethasone in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group. Blood 2006;108:799a.
Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007;25:4459–65.
Jagannath S, Dune BC, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005;129:776–83.
Mateos MV, Hernandez JM, Hernandez MI, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multi-center phase I/Il study. Blood 2006;108:2165–72.
Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bort-ezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br. J. Haematol 2005; 129:755–62.
Sagaster V, Ludwig H, Kaufmann H, et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 2007;21:164–68.
Zeldis JB, Williams BA, Thomas SD, Elsayed ME. S.T.E.P.S.: A comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 1999;21:319–30.
Bennet CL, Angelotta C, Yarnold PR, et al. Thalidomide- and lenalidomide-associ-ated thromboembolism among patients with cancer. JAMA 2006;296:2558–60.
Dimopoulos MA, Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004; 117:508–15.
Lonial S, Wailer EK, Richardson PG, et al. SUMMIT/CREST investigators risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005; 106:3777–84.
Palumbo A, Ambrosini MT, Benevolo G, et al. Bortezomib, melphalan, prednisone and thalidomide for relapsed multiple myeloma. Blood 2007;109:2767–72.
Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and rever-sibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113–20.
Mihelic R, Kaufman JL, Lonial S. Maintenance therapy in multiple myeloma. Leukemia 2007;21:1150–57.
Fritz E, Ludwig H. Interferon-{alpha} treatment in multiple myeloma: Meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol 2000;11:1427–36.
The Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001;113:1020–34.
Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002;99:3163–68.
Shustik C, Belch A, Robinson S, et al. Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: A National Cancer Institute of Canada Clinical Trials Group Study: MY.7. J Clin Oncol 2004;22 (Suppl 15): 651 Oa.
Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108:3289–94.
Acknowledgments
Supported in part by the Universitá degli Studi di Torino, Fondazione Neoplasie Sangue Onlus, Associazione Italiana Leucemie, Compagnia di S Paolo, Fondazione Cassa di Risparmio di Torino, Ministero dell'Universitá della Ricerca (MIUR), and Consiglio Nazionale delle Ricerche (CNR), Italy.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Sara, B., Antonio, P. (2008). Therapy for Patients not Eligible for Autologous Transplant. In: Lonial, S. (eds) Myeloma Therapy. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-564-0_8
Download citation
DOI: https://doi.org/10.1007/978-1-59745-564-0_8
Publisher Name: Humana Press
Print ISBN: 978-1-934115-82-4
Online ISBN: 978-1-59745-564-0
eBook Packages: MedicineMedicine (R0)